Enlivex Therapeutics Secures Japanese Patent Allowance
Ticker: ENLV · Form: 6-K · Filed: Oct 30, 2024 · CIK: 1596812
Sentiment: bullish
Topics: patent, intellectual-property, therapeutics
TL;DR
Enlivex just got a patent allowance in Japan for its immune modulator tech – big win for IP!
AI Summary
On October 30, 2024, Enlivex Therapeutics Ltd. announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861. This patent, titled "THERAPEUTIC USES OF ALLOMETRIC IMMUNE MODULATORS AND METHODS OF TREATMENT," covers the use of allocmetra (allocmetra) in treating various conditions, including autoimmune diseases, inflammatory diseases, and cancer. The allowance is a significant step towards strengthening Enlivex's intellectual property portfolio.
Why It Matters
This Japanese patent allowance strengthens Enlivex's intellectual property protection for its core technology, potentially enhancing its market position and future commercialization efforts for its therapeutic candidates.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a patent allowance, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Japanese Patent Office (company) — Issuing authority
- 2022-512861 (patent_application_number) — Specific patent application
- October 30, 2024 (date) — Date of announcement
FAQ
What is the title of the Japanese patent application that received a notice of allowance?
The title of the Japanese patent application number 2022-512861 is "THERAPEUTIC USES OF ALLOMETRIC IMMUNE MODULATORS AND METHODS OF TREATMENT."
What is the significance of the patent application number 2022-512861 for Enlivex Therapeutics?
The patent application number 2022-512861 covers the use of allocmetra in treating various conditions, including autoimmune diseases, inflammatory diseases, and cancer, and its allowance strengthens Enlivex's intellectual property portfolio.
Which patent office issued the notice of allowance to Enlivex Therapeutics?
The Japanese Patent Office issued the notice of allowance to Enlivex Therapeutics.
On what date did Enlivex Therapeutics announce the Japanese patent allowance?
Enlivex Therapeutics announced the Japanese patent allowance on October 30, 2024.
What is the primary subject matter covered by the allowed Japanese patent application?
The allowed Japanese patent application covers the therapeutic uses of allometric immune modulators and methods of treatment, specifically mentioning the use of allocmetra for conditions like autoimmune diseases, inflammatory diseases, and cancer.
Filing Stats: 241 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-10-30 08:01:16
Filing Documents
- ea0219014-6k_enlivex.htm (6-K) — 9KB
- ea021901401ex99-1_enlivex.htm (EX-99.1) — 9KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-091960.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: October 30, 2024